PANews reported on September 18th that crypto analyst The DeFi Investor wrote on the X platform: "The supply of BTC on centralized exchanges is at its lowest level in seven years. The scale of funds invested by institutions in purchasing Bitcoin in this cycle is incredible."PANews reported on September 18th that crypto analyst The DeFi Investor wrote on the X platform: "The supply of BTC on centralized exchanges is at its lowest level in seven years. The scale of funds invested by institutions in purchasing Bitcoin in this cycle is incredible."
BTC supply on centralized exchanges is at a 7-year low
PANews reported on September 18th that crypto analyst The DeFi Investor wrote on the X platform: "The supply of BTC on centralized exchanges is at its lowest level in seven years. The scale of funds invested by institutions in purchasing Bitcoin in this cycle is incredible."
Aviso legal: Los artículos republicados en este sitio provienen de plataformas públicas y se ofrecen únicamente con fines informativos. No reflejan necesariamente la opinión de MEXC. Todos los derechos pertenecen a los autores originales. Si consideras que algún contenido infringe derechos de terceros, comunícate a la dirección service@support.mexc.com para solicitar su eliminación. MEXC no garantiza la exactitud, la integridad ni la actualidad del contenido y no se responsabiliza por acciones tomadas en función de la información proporcionada. El contenido no constituye asesoría financiera, legal ni profesional, ni debe interpretarse como recomendación o respaldo por parte de MEXC.
También te puede interesar
Novo Nordisk cuts cash prices for Wegovy, Ozempic
The post Novo Nordisk cuts cash prices for Wegovy, Ozempic appeared on BitcoinEthereumNews.com. Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible. The Danish drugmaker is lowering the price of the drugs for existing cash-paying patients to $349 per month from $499 per month. But Novo Nordisk said the cash-pay cost of the highest dose of Ozempic will remain $499 per month. Also on Monday, Novo Nordisk launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. After that period, people move to the new standard monthly direct-to-consumer price. The company’s introductory offer ends on March 31. The announcements come days after President Donald Trump struck deals with Novo Nordisk and chief rival Eli Lilly to make their popular GLP-1 drugs easier for Americans to access and afford. Those agreements will involve cutting the prices the government pays for the drugs, introducing Medicare coverage of obesity drugs for the first time for certain patients and offering discounted medicines on the government’s new direct-to-consumer website launching in January called TrumpRx. “Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay,” said Dave Moore, Novo Nordisk’s head of U.S. operations, said in a release. “It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs for people living with chronic diseases like…
Compartir
BitcoinEthereumNews2025/11/17 21:30
Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.
Daily market key data review and trend analysis, produced by PANews.
Compartir
PANews2025/04/30 13:50
Crypto execs met with US lawmakers to discuss Bitcoin reserve, market structure bills
Lawmakers in the US House of Representatives and Senate met with cryptocurrency industry leaders in three separate roundtable events this week. Members of the US Congress met with key figures in the cryptocurrency industry to discuss issues and potential laws related to the establishment of a strategic Bitcoin reserve and a market structure.On Tuesday, a group of lawmakers that included Alaska Representative Nick Begich and Ohio Senator Bernie Moreno met with Strategy co-founder Michael Saylor and others in a roundtable event regarding the BITCOIN Act, a bill to establish a strategic Bitcoin (BTC) reserve. The discussion was hosted by the advocacy organization Digital Chamber and its affiliates, the Digital Power Network and Bitcoin Treasury Council.“Legislators and the executives at yesterday’s roundtable agree, there is a need [for] a Strategic Bitcoin Reserve law to ensure its longevity for America’s financial future,” Hailey Miller, director of government affairs and public policy at Digital Power Network, told Cointelegraph. “Most attendees are looking for next steps, which may mean including the SBR within the broader policy frameworks already advancing.“Read more
Compartir
Coinstats2025/09/18 03:30